blush, we are leaving our fair value estimate unchanged. We had long been puzzled by Endo's purchase of American Medical Systems in 2011, as the latter's device portfolio seemed like an awkward fit with the former's range of patent
March 2 (Reuters) - Medical device maker Boston Scientific Corp said it will buy Endo International Plc's American Medical Systems ' men's and prostate health business for up to $1.65 billion.
March 2 (Reuters) - Boston Scientific Corp said it will acquire Endo International Plc's American Medical Systems urology portfolio for up to $1.65 billion.
was $785 million, up 29% from the year-ago period thanks to solid organic growth and the acquisition of American Medical Systems in June 2011. Endo's legacy pharmaceutical business saw revenue of $443 million, an increase of 11
142 million and $52 million, respectively, to Endo's top line, driven by the firm's purchase of American Medical Systems and HealthTronics. Total revenues during fourth quarter were $803 million, a 57% increase over fourth
Similarly, devices and services sales increased 259% to $186 million thanks to the Endo's purchase of American Medical Systems earlier this year. Adjusted diluted earnings per share increased 45% to $1.25 from $0.86 in third
lifted its full-year outlook based on the timing of the American Medical Systems acquisition (completed in June) and strength in the ..... 8 million from the firm's recent acquisition of American Medical Systems . This represents a highly profitable segment for the
rating reflects the specialty pharmaceutical firm's much higher financial leverage after the $2.9 billion American Medical Systems (AMS) acquisition and Endo's ongoing dependence on Lidoderm, which contributes to its negative moat trend
Endo Pharmaceuticals ENDP announced Monday its intent to acquire American Medical Systems AMMD for $2.9 billion, including the repayment of $312 million of AMS' debt. While the $30 per share cash offering is well above
American Medical Systems AMMD posted third-quarter results that fell slightly short of our estimates on the top line, but came in ahead of our expectations